Summary of CLL trials presented at ASH 2016
Current research to overcome T-cell dysfunction in CLL and improve therapies
Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL
The importance of individually customized treatment for CLL patients
Are complex karyotypes reliable prognostic markers for CLL?